SCHEMBL5363218

SCHEMBL5363218

CS(=O)(=O)c1ccc(S(=O)(=O)NC2CCC(c3ccc(O)cc3O)CC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.44
RECQL P46063 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ALDH1A1 P00352 7/20 0.43
LMNA P02545 2/20 0.43
KMT2A Q03164 4/20 0.42
TDP1 Q9NUW8 1/20 0.42
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
ENPP2 Q13822 1/20 0.41
MEN1 O00255 3/20 0.41
DPP4 P27487 3/20 0.41
DPP7 Q9UHL4 3/20 0.41
HSD17B10 Q99714 1/20 0.40
PIK3CG P48736 1/20 0.40
PARG Q86W56 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
CACNA1B Q00975 1/20 0.40
APBA1 Q02410 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5363211 1.00 KDM4E (0.44) KDM4ERECQLSMN1; SMN2ALDH1A1LMNA
SCHEMBL5366806 0.90 ALDH1A1 (0.55) KDM4ERECQLSMN1; SMN2ALDH1A1LMNA
SCHEMBL5359940 0.90 ALDH1A1 (0.55) KDM4ERECQLSMN1; SMN2ALDH1A1LMNA
SCHEMBL5359944 0.90 ALDH1A1 (0.55) KDM4ERECQLSMN1; SMN2ALDH1A1LMNA
SCHEMBL5366825 0.88 STS (0.45) KDM4ERECQLSMN1; SMN2ALDH1A1LMNA
SCHEMBL5366823 0.88 STS (0.45) KDM4ERECQLSMN1; SMN2ALDH1A1LMNA
SCHEMBL5356347 0.88 KMT2A (0.48) KDM4ERECQLSMN1; SMN2ALDH1A1LMNA
SCHEMBL6599031 0.88 KMT2A (0.48) KDM4ERECQLSMN1; SMN2ALDH1A1LMNA
SCHEMBL5356341 0.88 KMT2A (0.48) KDM4ERECQLSMN1; SMN2ALDH1A1LMNA
SCHEMBL5374721 0.87 ALDH1A1 (0.48) KDM4ERECQLSMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6852747-B2 Resorcinol derivatives PFIZER INC. (US) 2005-02-08 US claimed
EP-1317425-B1 RESORCINOL DERIVATIVES PFIZER PROD INC (US) 2004-11-03 EP claimed
US-20030180236-A1 Resorcinol derivatives PFIZER PRODUCTS, INC. 2003-09-25 US claimed
US-20020114770-A1 Resorcinol derivatives PFIZER INC. 2002-08-22 US claimed
US-7282592-B2 Resorcinol derivatives WARNER-LAMBERT COMPANY (US) 2007-10-16 US disclosed
US-20070122367-A1 RESORCINOL DERIVATIVES PFIZER INC. (US) 2007-05-31 US disclosed
US-7173052-B2 Resorcinol derivatives PFIZER INC. (US) 2007-02-06 US disclosed
US-20050282899-A1 Resorcinol for lightening skin removing color BRADLEY STUART E 2005-12-22 US disclosed
US-6852747-B2 Resorcinol derivatives PFIZER INC. (US) 2005-02-08 US disclosed
EP-1317425-B1 RESORCINOL DERIVATIVES PFIZER PROD INC (US) 2004-11-03 EP disclosed
US-20030180236-A1 Resorcinol derivatives PFIZER PRODUCTS, INC. 2003-09-25 US disclosed
US-6590105-B2 For skin lightening or depigmentation; works by inhibiting tyrosinase in humans; kits WARNER-LAMBERT COMPANY 2003-07-08 US disclosed
US-20020114770-A1 Resorcinol derivatives PFIZER INC. 2002-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070122367-A1 RESORCINOL DERIVATIVES LRAT, NQO1, ALDH1A2 KDM4E 2885/4885RECQL 92/4885SMN1; SMN2 4867/4885
US-20030180236-A1 Resorcinol derivatives LRAT, NQO1, ALDH1A2 KDM4E 2885/4885RECQL 92/4885SMN1; SMN2 4867/4885
US-20050282899-A1 Resorcinol for lightening skin removing color RBP4, NQO1, ALDH1A2 KDM4E 1157/4885RECQL 109/4885SMN1; SMN2 4683/4885
US-20020114770-A1 Resorcinol derivatives LRAT, NQO1, ALDH1A2 KDM4E 2885/4885RECQL 92/4885SMN1; SMN2 4867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.